Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | WNT3A | P56704 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzimidazole SCHEMBL4371075 | 1.00 | KDM4E (0.51) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL158526 | 0.94 | SMN1; SMN2 (0.54) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL9028632 | 0.92 | SMN1; SMN2 (0.49) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL10531809 | 0.92 | KDM4E (0.49) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL16516335 | 0.90 | SMN1; SMN2 (0.57) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL8901469 | 0.90 | SMN1; SMN2 (0.57) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL2334176 | 0.90 | PRKCI (0.50) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL11810774 | 0.89 | KDM4E (0.46) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Terephthalamide SCHEMBL29216571 | 0.89 | PARP1 (0.54) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL4306997 | 0.89 | CTNNB1 (0.47) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104876878-B | - 2 alkyl substituted urea benzimidazoles compound of 5- aryl phenols and its application | 中国科学院广州生物医药与健康研究院 | 2018-04-27 | — | — | CN | claimed |
| CN-104876878-A | 5-aryl phenol-2 alkyl substituted urea benzimidazole compound and applications thereof | GUANGZHOU INST BIOMED & HEALTH | 2015-09-02 | — | — | CN | claimed |
| CN-114195972-B | PDMS material containing benzimidazolyl dynamic covalent bond, preparation method and application thereof | 四川大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-114195972-A | PDMS material containing benzimidazolyl dynamic covalent bond, preparation method and application thereof | 四川大学 | 2022-03-18 | — | — | CN | disclosed |
| US-20210198266-A1 | METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES | DUKE UNIVERSITY | 2021-07-01 | — | — | US | disclosed |
| EP-3840745-A1 | METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES | Duke University (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112654353-A | Methods and pharmaceutical compositions for treating ocular diseases | 杜克大学 | 2021-04-13 | — | — | CN | disclosed |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| WO-2020041344-A1 | METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES | DUKE UNIVERSITY (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| CN-108828110-A | The measuring method of benzimidazoles residues residual quantity in one breeder fat | 广东出入境检验检疫局检验检疫技术中心 | 2018-11-16 | — | — | CN | disclosed |
| WO-2013024427-A1 | NOVEL UREA DERIVATIVES AS TEC KINASE INHIBITORS AND USES THEREOF | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-02-21 | — | — | WO | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| WO-2012088266-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-2368905-A2 | Process for the control of production of fine chemicals | Metanomics GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2096177-A2 | Process for the production of lutein | Metanomics GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1974049-A2 | PROCESS FOR THE CONTROL OF PRODUCTION OF FINE CHEMICALS | Metanomics GmbH (DE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1953235-A2 | New genes related to a process for the production of fine chemicals | Metanomics GmbH (DE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1765857-A2 | PROCESS FOR THE PRODUCTION OF FINE CHEMICALS | Metanomics GmbH (DE) | 2007-03-28 | — | — | EP | disclosed |
| US-6380232-B1 | FOR THERAPY OF CANCER OR A VIRAL INFECTION IN WARM BLOODED ANIMALS, MAY BE USED IN COMBINATION WITH POTENTIATOR OR OTHER DRUG | THE PROCTER & GAMBLE COMPANY | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | KDM4E 668/4885PARP1 2115/4885SMN1; SMN2 2466/4885 |
| US-20210198266-A1 | METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES | CAMKK2, CILK1, CAMK2D | KDM4E 3323/4885PARP1 2668/4885SMN1; SMN2 1984/4885 |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | KDM4E 668/4885PARP1 2115/4885SMN1; SMN2 2466/4885 |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | FGFR3, FGFR4, FGFR2 | KDM4E 668/4885PARP1 2115/4885SMN1; SMN2 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.